Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib + Docetaxel in Previously Treated Advanced NSCLC
NCT02257619Phase 2Terminated
- Sponsor
- Incyte
- Start
- Sep 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of itacitinib in non-small cell lung cancer (NSCLC), sponsored by Incyte. Primary endpoint: Dose Limiting Toxicities at 21 days. Started Sep 2014; status: terminated.
02
Drugs
itacitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02257619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02257619.